Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs

Molecular and Cellular Biology

Volumn 17, Issue 1, 1997, Pages 364-377

  Schaefer, Brian C ^a,c   Strominger, Jack L ^a   Speck, Samuel H ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BURKITT LYMPHOMA; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; GENE TARGETING; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS GENOME; VIRUS LATENCY;

ANIMALIA; HUMAN HERPESVIRUS 4;

EID: 0031022961     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.1.364     Document Type: Article

References (85)

1. Altiok, E., J. Minarovits, H. Li-Fu, B. Contreras-Brodin, G. Klein, and I. Ernberg. 1992. Host-cell-phenotype-dependent control of BCR2/BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6. Proc. Natl. Acad. Sci. USA 89:905-909.
2. Barlow, D. P. 1993. Methylation and imprinting: from host defense to gene regulation? Science 260:309-310.
3. Bird, A. P. 1993. Functions for DNA methylation in vertebrates. Cold Spring Harbor Symp. Quant. Biol. 58:281-285.
4. Brandeis, M., D. Frank, I. Keshet, Z. Siegfreid, M. Mendelsohn, A. Nemes, V. Temper, A. Razin, and H. Cedar. 1994. Sp1 elements protect a CpG island from de novo methylation. Nature 371:435-438.
5. Brooks, L., Q. Y. Yao, A. B. Rickinson, and L. S. Young. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66:2689-2697.
6. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
7. Clark, S. J., J. Harrison, C. L. Paul, and M. Frommer. 1994. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 22:2990-2997.
8. Deacon, E. M., G. Pallesen, G. Niedobitek, J. Crocker, L. Brooks, A. B. Rickinson, and L. S. Young. 1993. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 177:339-349.
9. Deng, W. P., and J. A. Nikoloff. 1992. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. Anal. Biochem. 200:81-88.
10. Ernberg, I., K. Falk, J. Minarovits, P. Busson, T. Tursz, M. G. Masucci, and G. Klein. 1989. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J. Gen. Virol. 70: 2989-3002.
11. Evans, T. J., M. G. Jacquemin, and P. J. Farrell. 1995. Efficient EBV superinfection of group 1 Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology 206:866-877.
12. Fahraeus, R., J. L. Fu, I. Ernberg, I. Fincke, M. Rowe, G. Klein, E. Nilsson, M. Yadav, P. Busson, T. Tursz, and B. Kallin. 1988. Expression of EBV-encoded proteins in nasopharyngeal carcinoma. Int. J. Cancer. 42:329-338.
13. Farrell, P. J. 1989. Epstein Barr virus genome. Adv. Viral Oncol. 8:103-132.
14. Flemington, E. K., J. P. Lytle, C. Cayrol, A. M. Borras, and S. H. Speck. 1994. DNA-binding-defective mutants of the Epstein-Barr virus lytic switch activator Zta transactivate with altered specificities. Mol. Cell. Biol. 14:3041-3052.
15. Fogh, J., and G. Trempe. 1975. New human tumor cell lines, p. 115-159. In J. Fogh (ed.), Human tumor cell lines in vitro. Plenum Press, New York, N.Y.
16. Gilligan, K., H. Sato, P. Rajadurai, P. Busson, L. Young, A. Rickinson, T. Tursz, and N. Raab-Traub. 1990. Novel transcription from the Epstein-Barr virus terminal EcoRI fragment. DIJhet, in nasopharyngeal carcinoma. J. Virol. 64:4948-4956.
17. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.
18. Gregory, C. D., M. Rowe, and A. B. Rickinson. 1990. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71:1481-1495.
19. Groudine, M., R. Eisenman, and H. Weintraub. 1981. Chromatin structure of endogenous retroviral genes and activation by an inhibitor of DNA methylation. Nature 292:311-317.
20. Hayashi, M., T. Furuichi, S. Ren, E. Isogai, M. Nonoyama, and S. Namioka. 1994. Enhancement of mRNA synthesis from Marek's disease virus genome in the lymphoblastoid cell line, MDCC-MSB1, by 5-azacytidine. J. Vet. Med. Sci. 56:287-291.
21. Herbst, H., F. Dallenbach, M. Hummel, G. Niedobitek, S. Pileri, N. Muller-Lantzsch, and H. Stein. 1991. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc. Natl. Acad. Sci. USA 88:4766-4770.
22. Hinuma, Y., M. Konn, J. Yamaguchi, D. J. Wudarski, J. R. Blakeslee, Jr., and J. T. Grace, Jr. 1967. Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J. Virol. 1:1045-1051.
23. Hitt, M. M., M. J. Allday, T. Hara, L. Karran, M. D. Jones, P. Busson, T. Tursz, I. Ernberg, and B. E. Griffin. 1989. EBV gene expression in an NPC-related tumor. EMBO J. 8:2639-2651.
24. Honess, R. W., U. A. Gompels, B. G. Barrell, M. Craxton, K. R. Cameron, R. Staden, Y. N. Chang, and G. S. Hayward. 1989. Deviations from expected frequencies of CpG dinucleotides in herpesvirus DNAs may be diagnostic of differences in the states of their latent genomes. J. Gen. Virol. 70:837-855.
25. Jahner, D., H. Stuhlmann, C. L. Stewart, K. Harbers, J. Lohler, I. Simon, and R. Jaenisch. 1982. De novo methylation and expression of retroviral genomes during mouse embryogenesis. Nature 289:623-628.
26. Jahner, D., and R. Jaenisch. 1985. Chromosomal position and specific demethylation in enhancer sequences of germ line-transmitted retroviral genomes during mouse development. Mol. Cell. Biol. 5:2212-2220.
27. Jannson, A., M. Masucci, and L. Rymo. 1992. Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines. J. Virol. 66:62-69.
28. Jin, X. W., and S. H. Speck. 1992. Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter. J. Virol. 66:2846-2852.
29. Jones, C. H., S. D. Hayward, and D. R. Rawlins. 1989. Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites. J. Virol. 63:101-110.
30. Jones, K., C. Rivera, C. Sgadari, J. Franklin, E. Max, K. Bhatia, and G. Tosato. 1995. Infection of human endothelial cells with Epstein-Barr virus. J. Exp. Med. 182:1213-1221.
31. Kanamori, A., K. Ikuta, S. Ueda, S. Kato, and K. Hirai. 1987. Methylation of Marek's disease virus DNA in chicken T-lymphoblastoid cell lines. J. Gen. Virol. 68:1485-1490.
32. Karlin, S., E. S. Mocarski, and G. Schachtel. 1994. Molecular evolution of herpesviruses: genomic and protein sequence comparisons. J. Virol. 68: 1886-1902.
33. Karlin, S., W. Doerfler, and L. R. Cardon. 1994. Why is CpG suppressed in the genomes of virtually all small eukaryotic viruses but not in those of large eukaryotic viruses? J. Virol. 68:2889-2897.
34. Kawasaki, E. S. 1990. Amplification of RNA, p. 21-27. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to methods and applications. Academic Press, Inc., San Diego, Calif.
35. Klein, G., L. Dombos, and M. Gothosokar. 1972. Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB virus. Int. J. Cancer 10:44-57.
36. Klein, G. 1994. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77:791-793.
37. Kruczek, I., and W. Doerfler. 1982. The unmethylated state of promoter/ leader and 5′-regions of integrated adenovirus genes correlates with gene expression. EMBO J. 1:409-414.
38. Laird, P. W., and R. Jaenisch. 1994. DNA methylation and cancer. Hum. Mol. Genet. 3:1487-1495.
39. Langner, K. D., L. Vardimon, D. Renz, and W. Doerfler. 1984. DNA methylation of three 5′ C-C-G-G 3′ sites in the promoter and 5′ region inactivate the E2a gene of adenovirus type 2. Proc. Natl. Acad. Sci. USA 81:2950-2954.
40. Lear, A. L., M. Rowe, M. G. Kurilla, S. Lee, S. Henderson, E. Kieff, and A. B. Rickinson. 1992. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J. Virol. 66:7461-7468.
41. Lerman, M. I., A. Sakai, K. T. Yao, and N. H. Colburn. 1987. DNA sequences in human nasopharyngeal carcinoma cells that specify susceptibility to tumor promoter-induced neoplastic transformation. Carcinogenesis 8:121-127.
42. Li, E., C. Beard, and R. Jaenisch. 1993. Role for DNA methylation in genomic imprinting. Nature 366:362-365.
43. Li, Q. X., L. S. Young, G. Niedobitek, C. W. Dawson, M. Birkenbach, F. Wang, and A. B. Rickinson. 1992. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 356:347-350.
44. MacLeod, D., J. Charlton, J. Mullins, and A. P. Bird. 1994. Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev. 8:2282-2292.
45. Masucci, M. G., B. Contreras-Salazar, E. Ragnar, K. Falk, J. Minarovits, I. Ernberg, and G. Klein. 1989. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line Rael. J. Virol. 63:3135-3141.
46. Merlo, A., J. G. Herman, L. Mao, D. J. Lee, E. Gabrielson, P. C. Burger, S. B. Baylin, and D. Sidransky. 1995. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1:686-692.
47. Milman, G., and E. S. Hwang. 1987. Epstein-Barr virus nuclear antigen forms a complex that binds with high concentration dependence to a single DNA-binding site. J. Virol. 61:465-471.
48. Minarovits, J., L.-F. Hu, Z. Marcsek, S. Minarovits-Kormuta, G. Klein, and I. Ernberg. 1992. RNA polymerase III-transcribed EBER 1 and 2 transcriptional units are expressed and hypomethylated in the major Epstein-Barr virus-carrying cell types. J. Gen. Virol. 73:1687-1692.
49. Minarovits, J., L.-F. Hu, S. Minarovits-Kormuta, G. Klein, and I. Ernberg. 1994. Sequence-specific methylation inhibits the activity of the Epstein-Barr virus LMP1 and BCR2 enhancer-promoter regions. Virology 200:601-667.
50. Miyashita, E. M., B. Yang, K. M. C. Lam, D. H. Crawford, and D. A. Thorley-Lawson. 1995. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80:593-601.
51. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157-168.
52. 51a.Nonkwelo, C., J. Skinner, A. Bell, A. Rickinson, and J. Sample. 1996. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J. Virol. 70:623-627.
53. Nonoyama, M., A. Tanaka, S. Silver, and R. Glaser. 1978. Transcription of Epstein-Barr virus genomes in human lymphoblastoid cells and in somatic cell hybrids of Burkitt's lymphoma. IARC Sci. Publ. 24:559-563.
54. Pallesen, G., S. J. Hamilton-Dutoit, M. Rowe, and S. L. Young. 1991. Expression of Epstein-Barr virus latent gene products in tumor cells of Hodgkin's disease. Lancet 337:320-322.
55. Paterson, R. L. K., C. A. Kelleher, J. E. Streib, T. D. Amankonah, J. W. Xu, J. F. Jones, and E. W. Gelfand. 1995. Activation of human thymocytes after infection by EBV. J. Immunol. 154:1440-1449.
56. Puglielli, M. T., M. Woisetschlaeger, and S. H. Speck. 1996. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J. Virol. 70:5758-5768.
57. Raizis, A. M., F. Schmitt, and J.-P. Jost. 1995. A bisalfite method of 5-methylcytosine mapping that minimizes template degradation. Anal. Biochem. 226:161-166.
58. Razin, A., and H. Cedar. 1991. DNA methylation and gene expression. Microbiol. Rev. 55:451-458.
59. Robertson, K. D., S. D. Hayward, P. D. Ling, D. Samid, and R. F. Ambinder. 1995. Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol. Cell. Biol. 15:6150-6159.
60. Rooney, C. M., M. Rowe, L. E. Wallace, and A. B. Rickinson. 1985. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature 317:629-631.
61. Rowe, M., D. Rowe, C. Gregory, L. S. Young, P. Farrell, H. Rupani, and A. B. Rickinson. 1987. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6:2743-2751.
62. Rowe, M., and C. Gregory. 1989. Epstein-Barr virus and Burkitt's lymphoma. Adv. Viral Oncol. 8:237-259.
63. Rowe, M., A. L. Lear, D. Croom-Carter, A. H. Davies, and A. B. Rickinson. 1992. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66:122-131.
64. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989 Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
65. Sample, J., L. Brooks, C. Sample, L. Young, M. Rowe, C. Gregory, A. Rickinson, and E. Kieff. 1991. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc. Natl. Acad. Sci. USA 88:6343-6347.
66. Sample, J., E. B. D. Henson, and C. Sample. 1992. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J. Virol. 66:4654-4661.
67. Sato, H., T. Takimoto, S. Tanaka, H. Ogura, K. Shiraishi, and J. Tanaka. 1989. Cytopathic effects induced by Epstein-Barr virus replication in epithelial nasopharyngeal carcinoma hybrid cells. J. Virol. 63:3555-3559.
68. Schaefer, B. C., M. Woisetschlaeger, J. L. Strominger, and S. H. Speck. 1991. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes. Proc. Natl. Acad. Sci. USA 88:6550-6554.
69. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1995. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines. J. Virol. 69:5039-5047.
70. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1995. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group 1 Burkitt lymphoma cell lines. Proc. Natl. Acad. Sci. USA 92:10565-10569.
71. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1996. A simple reverse transcriptase PCR assay to distinguish EBNA1 gene transcripts associated with type I and II latency from those arising during induction of the viral lytic cycle. J. Virol. 70:8204-8208.
72. 70a.Schaefer, B. C., E. Paulson, J. L. Strominger, and S. H. Speck. Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency. Mol. Cell. Biol., in press.
73. Schlager, S., S. H. Speck, and M. Woisetschläger. 1996. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells. J. Virol. 70:3561-3570.
74. Schweizer, M., U. Fleps, A. Jackle, R. Renne, R. Turek, and D. Neumann-Haefelin. 1993. Simian foamy virus type 3 (SFV-3) in latently infected Vero cells: reactivation by demethylation of proviral DNA. Virology 192:663-666.
75. Shibata, D., and L. M. Weiss. 1992. Epstein-Barr virus-associated gastric adenoearcinoma. Am. J. Pathol. 140:769-774.
76. Shimizu, N., A. Tanabe-Tochikura, Y. Kuroiwa, and K. Takada. 1994. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J. Virol. 68:6069-6073.
77. Speck, S. H., A. J. Pfitzner, and J. L. Strominger. 1986. An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide. Proc. Natl. Acad. Sci. USA 83:9298-9302.
78. 75a.Speck, S. H., and J. L. Strominger. 1989. Transcription of the Epstein-Barr virus in latently infected, growth transformed lymphocytes. Adv. Viral Oncol. 8:133-150.
79. Sundstrom, C., and K. Nilsson. 1976. Establishment and characterization of a human histiocytic lymphoma cell-line (U-937). Int. J. Cancer 7:565-577.
80. Takada, K., K. Horinouchi, Y. Ono, T. Aya, M. Osato, M. Takahashi, and S. Hayasaka. 1991. An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes 5:147-156.
81. Takimoto, T. 1979. Experimental studies on viral etiology of Epstein-Barr (EBV) in nasopharyngeal carcinoma (NPC): establishment of EBV infection on human epithelial cells derived from nasopharyngcal tissues. J. Otolaryngol. Jpn. 82:119-135.
82. Takimoto, T., M. Kamide, and R. Umeda. 1984. Establishment of Epstein-Barr virus (EBV)-associated nuclear antigen (EBNA)-positive nasopharyngeal carcinoma hybrid cell line (NPC-KT). Arch. Otolaryngol. 239:87-92.
83. Wang, F., A. Marchini, and E. Kieff. 1991. Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells. J. Virol. 65:1701-1709.
84. Woisetschlaeger, M., J. L. Strominger, and S. H. Speck. 1989. Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes. Proc. Natl. Acad. Sci. USA 86:6498-6502.
85. Woisetschlaeger, M., C. N. Yandava, L. A. Furmanski, J. L. Strominger, and S. H. Speck. 1990. Promoter switching in Epstein-Barr virus during the initial stages of infection. Proc. Natl. Acad. Sci. USA 87:1725-1729.